BioSpace News Archive

Generation Bio, a company leading a new generation of gene therapy, today announced the company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020.

CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmaceutical supply chain together.

Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces the appointment of Robert Cobuzzi, Jr., Ph.D., 55, to the Company’s board of directors, effective immediately.

Collaboration Expands To Include Renal Cell Carcinoma And Prostate Cancer, Including A Focus On Real-World Data Products For Novel Non-Interventional Studies For Potential Regulatory Submissions

Sten R. Sörensen, will present at Biotech Showcase™ 2020 being held January 13-15, 2020 at the Hilton San Francisco Union Square.

Seasoned Stroke Care Executive Joins a Strong Lineup of Leadership as Company Initiates Commercialization of Breakthrough Technologies

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today provided an update on recent positive regulatory interactions on the EDP1815 Phase 2 trial design, resulting in a reduction in the overall development plan timeline to registration.

HEALIOS K.K. (“Healios”) has been moving forward with efforts to create next generation immunotherapies for solid tumors by combining its iPS cell and gene editing technology expertise.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday, February 6, 2020, before the U.S. financial markets open.

RhoVac AB (“RhoVac”) announces today, on 10th January 2020, that the company has received approval from Beligian FAMHP (Federal Agency for Medicines and Health Products) and German Federal Institute for Vaccines and Biomedicines for starting the clinical phase IIb study in prostate cancer, a multicenter study entitled RhoVac-002 (“BRaVac”).